Company Overview of Celgene Cellular Therapeutics
Celgene Cellular Therapeutics engages in the research, recovery culture-expansion, preservation, development, and distribution of placental cells. The company develops placental cells, including stem and progenitor cells as therapeutic agents. It discovers and develops therapeutics from cells derived from the human placenta, as well as from the umbilical cord. The company develops stem cells for therapeutic applications in cancer, as well as autoimmune, cardiovascular, neurological, and degenerative diseases. It also operates a private umbilical cord blood bank. The company was formerly known as Anthrogenesis Corp. and changed its name to Celgene Cellular Therapeutics in 2002. Celgene Cellul...
7 Powder Horn Drive
Warren, NJ 07059-5190
Key Executives for Celgene Cellular Therapeutics
Chief Executive Officer, President and Director
Compensation as of Fiscal Year 2015.
Celgene Cellular Therapeutics Key Developments
BioCision, LLC to Develop Customized ThawSTAR Automated Cell Thawing System for Celgene Cellular Therapeutics
Jun 1 15
BioCision, LLC announced that it will collaborate with Celgene Cellular Therapeutics (CCT) to accelerate the development of a cell thawing solution based on BioCision's proprietary ThawSTAR™ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease. Conventional thawing methods, including swirling vials in warm water baths or rolling vials between hands can result in variable cell viabilities and can increase contamination concerns. BioCision’s ThawSTAR system utilizes a patent pending adaptive sensing technology that incorporates algorithms to deliver a consistent and reproducible thaw profile and endpoint to each vial, thus providing a standardized thawing process, eliminating variability that could have a detrimental effect on the safety and efficacy of the cell therapy, and providing a significant reduction in cell handling risk in a clinical setting. The new ThawSTAR automated cell thawing system that will be developed as a result of this collaboration is an expansion of BioCision’s technology platform and will be made available commercially. BioCision is also developing other vial formats to address the needs of the larger cell therapy market.
Alliqua Biomedical Amends Exclusive Licensing Agreement with Celgene Cellular Therapeutics
May 13 15
Alliqua Biomedical announced that it has amended its exclusive licensing agreement with Celgene Cellular Therapeutics (CCT), in the advanced tissue market. This amended agreement provides Alliqua with the right to develop and market CCT's connective tissue matrix product (CTM). Celgene Cellular Therapeutics' CTM product is derived from human placental tissue and will be launched by Alliqua upon commercialiasation. The CTM product is the third tissue product Alliqua has licensed from Celgene, following Biovance, Human Amniotic Membrane Allograft and Placental Extra Cellular Matrix, also in development. Alliqua plans to launch connective tissue matrix mid 2016 to compete in the approximately USD 660 million advanced tissue market, along with its Biovance Human Amniotic Membrane Allograft, the first product introduced through its Celgene partnership in 2014.
Alliqua Amends Licensing Agreement with Celgene Cellular Therapeutics to Market Biovance
Oct 6 14
Alliqua announced that it has amended a licensing agreement with Celgene Cellular Therapeutics, giving Aliqua the right to market advanced wound care product Biovance for podiatric and orthopedic applications. Biovance is a drug used to manage non-infected wounds including chronic and acute diabetic, pressure, venous and chronic vascular ulcers, and surgical and trauma woulds such as abrasions, lacerations and second-degree burns. Podiatrists use Biovance for sports medicine purposes.
Similar Private Companies By Industry
Recent Private Companies Transactions